Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.
Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.
All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.
On January 1, 2022, Innate Pharma reported a total of 79,542,627 ordinary shares outstanding and 6,514 preferred shares from 2016, alongside 7,581 preferred shares from 2017. The total theoretical voting rights amount to 80,300,467, while exercisable voting rights total 80,281,892. This disclosure complies with French regulations and aims to keep stakeholders informed of the company's share structure.
Innate Pharma is focused on oncology, developing therapeutic antibodies to combat cancer.
Innate Pharma SA has secured €28.7M in non-dilutive financing through two loans from Société Générale and BNP Paribas, aimed at enhancing its cash reserves and supporting research and development. These loans are primarily guaranteed by the French state and have a one-year term with a five-year extension option. The financing is part of government measures to aid businesses during the COVID-19 pandemic. Innate Pharma focuses on clinical-stage oncology, developing therapeutic antibodies to improve cancer treatment outcomes.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in upcoming virtual investor conferences. Key dates include the ODDO BHF Digital Forum on January 6, 2022, and the H.C. Wainwright BIOCONNECT Virtual Conference with a fireside chat on January 10, 2022. Additionally, the Innate Pharma Virtual Corporate Access Event will occur from January 10-13, 2022. As a clinical-stage oncology-focused biotech, Innate Pharma is dedicated to advancing therapies using immunology to treat cancer.
Innate Pharma announced the initiation of a Phase 1/2 clinical trial for IPH6101/SAR443579, a novel NK cell engager targeting CD123 in patients with relapsed/refractory AML, B-ALL, or HR-MDS. Sponsored by Sanofi, the trial aims to assess safety, pharmacokinetics, and initial clinical activity. This marks the first clinical advancement of Innate's ANKET™ platform, noted for its promising pre-clinical results, including significant anti-leukemia activity and favorable safety profiles. The trial's start triggers a milestone payment from Sanofi, part of a broader collaboration for developing bispecific NK cell engagers.
Innate Pharma announced promising data from a Phase 2 study on the chemo-free triplet therapy combining monalizumab, cetuximab, and durvalumab for treating recurrent or metastatic head and neck cancer. Presented at the ESMO Immuno-Oncology Congress 2021, the therapy demonstrated a 32.5% overall response rate and a 58.6% survival rate at 12 months. Key results include 40 patients enrolled and a median overall survival of 15 months. The safety profile was deemed acceptable, with low discontinuation rates. Innate plans future collaboration with AstraZeneca on this treatment.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will present new Phase 2 data on the triplet combination of monalizumab, cetuximab, and durvalumab for treating recurrent or metastatic head and neck squamous cell cancer at the ESMO Immuno-oncology Congress 2021, held virtually from December 8-11, 2021. This data focuses on first-line treatment in chemo-naïve patients. Additionally, an educational session will highlight ANKETTM, the company's NK cell engager platform. The oral presentation is scheduled for December 9, 2021.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in the Evercore ISI 4th Annual HealthConX Virtual Conference on December 1, 2021. The fireside chat will take place from 5:20-5:40 pm CET (11:20-11:40 am ET). Innate Pharma focuses on developing therapeutic antibodies to enhance cancer treatment outcomes. The company has established significant partnerships with industry leaders, including Bristol-Myers Squibb and AstraZeneca, and is headquartered in Marseille, France, with a U.S. office in Rockville, MD.
Innate Pharma announced significant updates on its pipeline and financials for the first nine months of 2021. Key highlights include the advancement of monalizumab to Phase 3 after positive Phase 2 results in NSCLC, and promising pre-clinical data for ANKET™ targeting acute myeloid leukemia. The company's cash position stood at €141.8 million as of September 30, 2021, with revenues of €10.3 million for the same period, down from €33.6 million in 2020. The CEO emphasized a commitment to advancing its R&D strategy and collaborations, particularly with AstraZeneca.
Innate Pharma announced the presentation of pre-clinical data on IPH6101/SAR443579, a novel NK cell engager targeting CD123 in acute myeloid leukemia (AML), at the SITC Annual Meeting. The data demonstrated a favorable safety profile and potent antitumor activity, including efficacy against ADCC-resistant AML cells. These results support advancing IPH6101/SAR443579 into clinical trials. The collaboration with Sanofi enhances development opportunities, with the potential for significant milestone payments and royalties for Innate Pharma.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) will host a conference call on November 16, 2021, at 2 p.m. CET / 8 a.m. ET to update on business progress from Q3 2021. The call will feature CEO Mondher Mahjoubi and CMO Joyson Karakunnel. Investors can join via webcast or phone, with specific dial-in numbers provided. Innate Pharma focuses on oncology, leveraging therapeutic antibodies and Natural Killer cell biology, and has partnerships with major industry players like Bristol-Myers Squibb and AstraZeneca.
